株式会社ユカリア Logo

株式会社ユカリア

Management, DX, and data solutions for healthcare and long-term care providers.

286A | T

Overview

Corporate Details

ISIN(s):
JP3946900002
LEI:
Country:
Japan
Address:
千代田区霞が関3丁目2番5号 霞が関ビルディング19階
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Eucalia Inc. is a healthcare services company dedicated to transforming the medical and long-term care sectors. Its core business is providing management and operational support for hospitals and care facilities. The company offers a comprehensive suite of services, including management consulting, medical digital transformation (DX) solutions, and medical data utilization. Eucalia also directly operates facilities for the elderly. Its client base includes hospitals, care facilities, pharmaceutical companies, and academic institutions. The company operates on the principle of 'Sanpo-yoshi' (good for all three parties), aiming to build a sustainable ecosystem that improves the quality of life for facility management, healthcare workers, and patients alike, thereby strengthening the social infrastructure of care.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 09:21
Interim Report
確認書
Japanese 8.6 KB
2025-08-14 09:19
Interim Report
半期報告書-第21期(2025/01/01-2025/12/31)
Japanese 295.4 KB
2025-06-18 02:30
M&A Activity
臨時報告書
Japanese 20.2 KB
2025-06-05 09:46
M&A Activity
臨時報告書
Japanese 32.5 KB
2025-05-15 09:01
M&A Activity
臨時報告書
Japanese 30.0 KB
2025-05-15 07:43
M&A Activity
臨時報告書
Japanese 29.9 KB
2025-03-28 06:37
Post-Annual General Meeting Information
臨時報告書
Japanese 25.3 KB
2025-03-28 06:36
Registration Form
確認書
Japanese 8.6 KB
2025-03-28 06:36
Governance Information
内部統制報告書-第20期(2024/01/01-2024/12/31)
Japanese 23.3 KB
2025-03-28 06:35
Annual Report
有価証券報告書-第20期(2024/01/01-2024/12/31)
Japanese 2.0 MB
2025-02-17 02:05
M&A Activity
臨時報告書
Japanese 27.0 KB
2024-12-03 07:30
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.1 MB
2024-11-25 07:30
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.1 MB
2024-11-08 07:30
Registration Form
有価証券届出書(新規公開時)
Japanese 4.0 MB
2024-03-29 07:00
Foreign Filer Report
親会社等状況報告書(内国会社)-第19期(2023/01/01-2023/12/31)
Japanese 25.1 KB

Automate Your Workflow. Get a real-time feed of all 株式会社ユカリア filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for 株式会社ユカリア

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for 株式会社ユカリア via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Advancing high-grade copper and precious metal projects from discovery to production.
Canada
COR
Cantargia Logo
Develops antibody treatments targeting IL1RAP for cancer and autoimmune/inflammatory diseases.
Sweden
CANTA
Captor Therapeutics S.A. Logo
Developing TPD therapeutics for oncology and autoimmune diseases with its Optigrade™ platform.
Poland
CTX
Cardiff Oncology, Inc. Logo
Clinical-stage biotech developing a PLK1 inhibitor to treat resistant cancers.
United States of America
CRDF
Cardio Diagnostics Holdings, Inc. Logo
AI-powered epigenetic and genetic tests for early detection of heart disease risk.
United States of America
CDIO
Cardiol Therapeutics Inc. Logo
Develops oral cannabidiol therapies for inflammatory and fibrotic heart diseases.
United States of America
CRDL
CareDx, Inc. Logo
Precision diagnostics and surveillance solutions for the organ transplant journey.
United States of America
CDNA
Offers one-stop BPO, CRM, and staffing for admin, manufacturing, and logistics.
Japan
6070
Caris Life Sciences, Inc. Logo
Pioneering precision cancer care via AI-powered molecular profiling and diagnostics.
United States of America
CAI
Carna Biosciences, Inc. Logo
Develops kinase inhibitor drugs for oncology/autoimmune diseases & offers discovery support services.
Japan
4572

Talk to a Data Expert

Have a question? We'll get back to you promptly.